These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38364806)

  • 1. Personalized treatment selection via product partition models with covariates.
    Pedone M; Argiento R; Stingo FC
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian predictive modeling for genomic based personalized treatment selection.
    Ma J; Stingo FC; Hobbs BP
    Biometrics; 2016 Jun; 72(2):575-83. PubMed ID: 26575856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of subpopulations with distinct treatment benefit rate using the Bayesian tree.
    Shen C; Hu Y; Li X; Wang Y; Chen PS; Buxton AE
    Biom J; 2016 Nov; 58(6):1357-1375. PubMed ID: 27356196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the Optimal Personalized Treatment Strategy Based on Selected Variables to Prolong Survival via Random Survival Forest with Weighted Bootstrap.
    Shen J; Wang L; Daignault S; Spratt DE; Morgan TM; Taylor JMG
    J Biopharm Stat; 2018; 28(2):362-381. PubMed ID: 28934002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clustering blood donors via mixtures of product partition models with covariates.
    Argiento R; Corradin R; Guglielmi A; Lanzarone E
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying treatment responders using counterfactual modeling and potential outcomes.
    Porcher R; Jacot J; Wunder JS; Biau DJ
    Stat Methods Med Res; 2019; 28(10-11):3346-3362. PubMed ID: 30298794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating genomic signatures for treatment selection with Bayesian predictive failure time models.
    Ma J; Hobbs BP; Stingo FC
    Stat Methods Med Res; 2018 Jul; 27(7):2093-2113. PubMed ID: 27807177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Hierarchical Bayesian Model for Personalized Survival Predictions.
    Bellot A; van der Schaar M
    IEEE J Biomed Health Inform; 2019 Jan; 23(1):72-80. PubMed ID: 29994056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Product Partition Model With Regression on Covariates.
    Müller P; Quintana F; Rosner GL
    J Comput Graph Stat; 2011 Mar; 20(1):260-278. PubMed ID: 21566678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian multivariate hierarchical model for developing a treatment benefit index using mixed types of outcomes.
    Wu D; Goldfeld KS; Petkova E; Park HG
    BMC Med Res Methodol; 2024 Sep; 24(1):218. PubMed ID: 39333874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A probability based method for selecting the optimal personalized treatment from multiple treatments.
    Siriwardhana C; Zhao M; Datta S; Kulasekera KB
    Stat Methods Med Res; 2019 Mar; 28(3):749-760. PubMed ID: 29145777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
    Gu X; Yin G; Lee JJ
    Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized treatment selection using data from crossover designs with carry-over effects.
    Siriwardhana C; Kulasekera KB; Datta S
    Stat Med; 2019 Dec; 38(28):5391-5412. PubMed ID: 31637762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Borrowing strength with nonexchangeable priors over subpopulations.
    Leon-Novelo LG; Bekele BN; Müller P; Quintana F; Wathen K
    Biometrics; 2012 Jun; 68(2):550-8. PubMed ID: 22040065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient screening of predictive biomarkers for individual treatment selection.
    Sugasawa S; Noma H
    Biometrics; 2021 Mar; 77(1):249-257. PubMed ID: 32294246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers.
    Yada S
    Int J Biostat; 2021 Jun; 18(1):109-125. PubMed ID: 34114385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSICA: Decision trees for probabilistic subgroup identification with categorical treatments.
    Sysoev O; Bartoszek K; Ekström EC; Ekholm Selling K
    Stat Med; 2019 Sep; 38(22):4436-4452. PubMed ID: 31246349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.